Stevanato Group SpANYSE:STVN
- LAST PRICE19.9850
- TODAY'S CHANGE (%)0.0650 (0.3263%)
- Bid / Lots19.8000/ 1
- Ask / Lots19.9900/ 2
- Open / Previous Close19.9400 / 19.9200
- Day Range
- 52 Week Range
- Volume25,618
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | STVN |
|---|---|---|
| 09:32 ET | 1045 | 19.94 |
| 09:42 ET | 1916 | 20 |
| 09:44 ET | 500 | 20 |
| 09:50 ET | 9205 | 19.885 |
| 09:51 ET | 688 | 19.995 |
| 09:53 ET | 2700 | 20 |
| 09:57 ET | 200 | 20 |
| 10:00 ET | 2512 | 20 |
| 10:02 ET | 100 | 20 |
| 10:04 ET | 600 | 20 |
| 10:09 ET | 500 | 20 |
| 10:15 ET | 200 | 20 |
| 10:18 ET | 3248 | 19.985 |
Nov 11, 2024
Stevanato Group to Present at Upcoming Investor Conferences, from 6:32AM ET on Monday Nov 11, 2024 by Dow Jones
6:32AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 5, 2024
Press Release: Stevanato Group Reports Financial Results for the Third Quarter of 2024, from 6:31AM ET on Tuesday Nov 05, 2024 by Dow Jones
6:31AM ET on Tuesday Nov 05, 2024 by Dow JonesStevanato Group Reports Financial Results for the Third Quarter of 2024, from 6:31AM ET on Tuesday Nov 05, 2024 by Dow Jones
6:31AM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Stevanato Group SpA | 6.0B | 44.6x | --- |
Merit Medical Systems Inc | 6.1B | 50.6x | +14.05% |
Lantheus Holdings Inc | 6.3B | 14.8x | +35.30% |
Inspire Medical Systems Inc | 5.7B | 175.5x | --- |
Haemonetics Corp | 4.3B | 36.7x | +17.09% |
Procept Biorobotics Corp | 5.1B | -49.7x | --- |
Company Information
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
Contact Information
- Headquarters
- Piombino Dese (Pd) Via Molinella, 17PIOMBINO DESE, Italy 35017
- Phone
- ---
- Fax
- ---
Executives
- Executive Chairman of the Board, Chief Executive Officer
- Franco Stevanato
- Emeritus Chairman
- Sergio Stevanato
- Vice Chairman of the Board
- Marco Stevanato
- Chief Financial Officer
- Marco Lago
- President, Americas
- Riccardo Butta
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.0B |
|---|---|
Revenue (TTM) | $1.1B |
Shares Outstanding | 302.8M |
Dividend Yield | 0.29% |
Annual Dividend Rate | 0.0530 EUR |
Ex-Dividend Date | 06-04-24 |
Pay Date | 07-15-24 |
Beta | 0.59 |
EPS | $0.45 |
Book Value | $4.49 |
P/E Ratio | 44.6x |
Price/Sales (TTM) | 5.2 |
Price/Cash Flow (TTM) | 29.4x |
Operating Margin | 14.47% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
